NCT04732845View on ClinicalTrials.gov

Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 26, 2021

Primary Completion Date

September 1, 2025

Study Completion Date

December 1, 2039

Conditions
Non Hodgkin LymphomaAcute Lymphoblastic LeukemiaChronic Lymphocytic Leukemia
Interventions
BIOLOGICAL

Fully human anti CD19 CAR-T Cell Dose

"Level -1 (1 x 10\^5 cells/kg) Level 1 \[Starting Dose\] (5 x 10\^5 cells/kg) Level 2 (1 x 10\^6 cells/kg) Level 3 (2 x 10\^6 cells/kg)~Infusion of CAR-T cells will occur over 5-30 minutes."

DRUG

Fludarabine

25 mg/m2 daily from day -5 to -3

DRUG

Cyclophosphamide

60mg/Kg on day -6

Trial Locations (1)

44106-5065

University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Benjamin Tomlinson

OTHER

NCT04732845 - Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies | Biotech Hunter | Biotech Hunter